Synthesis, Structural Characterization and Antiproliferative Activity of Gold(I) and Gold(III) Complexes Bearing Thioether-Functionalized N-Heterocyclic Carbenes

Riccardo de Marco, Marco Dal Grande, Marco Baron, Laura Orian, Claudia Graiff, Thierry Achard, Stéphane Bellemin-laponnaz, Alexander Pöthig, Cristina Tubaro

► To cite this version:

Riccardo de Marco, Marco Dal Grande, Marco Baron, Laura Orian, Claudia Graiff, et al.. Synthesis, Structural Characterization and Antiproliferative Activity of Gold(I) and Gold(III) Complexes Bearing Thioether-Functionalized N-Heterocyclic Carbenes. *European Journal of Inorganic Chemistry*, 2021, 2021 (40), pp.4196-4206. 10.1002/ejic.202100495 . hal-03401905

HAL Id: hal-03401905

<https://hal.science/hal-03401905>

Submitted on 25 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Synthesis, Structural Characterization and Antiproliferative Activity of Gold(I) and Gold(III) Complexes Bearing Thioether-Functionalized N-Heterocyclic Carbenes

Riccardo De Marco,^{†[a,b]} Marco Dal Grande,^{†[a]} Marco Baron,^[a] Laura Orian,^[a] Claudia Graiff,^[c] Thierry Achard,^{*[b]} Stéphane Bellemin-Laponnaz,^{*[b]} Alexander Pöthig,^[d] and Cristina Tubaro^{*[a]}

[a] R. De Marco, M. Dal Grande, Dr. M. Baron, Prof. Dr. L. Orian, Prof. Dr. C. Tubaro

Dipartimento di Scienze Chimiche

Università degli Studi di Padova

via Marzolo 1, 35131 Padova, Italy.

† These authors contributed equally to this work.

[b] Dr. T. Achard, Dr. S. Bellemin-Laponnaz

Institut de Physique et Chimie des Matériaux de Strasbourg

CNRS-Université de Strasbourg UMR7504

23 rue du Loess BP 43, 67034 Strasbourg, France.

[c] Prof. Dr. C. Graiff

Dipartimento di Scienze Chimiche, della Vita e della Sostenibilità Ambientale

Università degli Studi di Parma

Parco Area delle Scienze 17/A, 43124 Parma, Italy.

[d] Dr. A. Pöthig

Department of Chemistry & Catalysis Research Center

Technische Universität München

Ernst-Otto-Fischer-Straße 1, Garching bei München, D-85748, Germany.

Supporting information for this article is given via a link at the end of the document.

Abstract: A series of gold(I) and gold(III) complexes with N-heterocyclic carbene ligands functionalized with a pendant thioether group (NHC-SR) was synthesized with straightforward procedures and characterized in solution with NMR spectroscopy and ESI-MS spectrometry, as well as in the solid state by means of single crystal X-ray diffraction analysis. Selected experimental aspects were rationalized through relativistic DFT calculations. The gold(I) and gold(III) complexes displayed moderate *in vitro* cytotoxicity towards breast cancer cells MCF7.

Introduction

Late transition metal complexes bearing N-heterocyclic carbene ligands (NHCs) have found tremendous successful applications in the last few decades, for examples as homogenous catalysts, metalodrugs or luminescent materials. The success of this class of ligands can be attributed to their strong donating abilities, which confers to the corresponding metal complexes a very high stability, straightforward synthetic procedures and the possibility to tune their steric and electronic properties by changing the nitrogen or backbone substituents.^[1–4] Additionally, it is possible to introduce a second donor group (usually P, O or N)^[5–10] in the pendant nitrogen substituent, thus giving possibly bidentate ligands.^[11] In this regard, N-heterocyclic carbenes bearing a thioether pendant function (Chart 1) are also an interesting class of ligands, that has found application both in homogeneous catalysis and bioinorganic chemistry. Particularly, these S-functionalized NHCs may show a chelating ability which results in the formation of highly stable complexes with a strong σ -donor function (the NHC moieties) and a weaker one (the sulfur atom).^[12–17] The hemilabile equilibrium of sulfur chelating ligand can be of high importance for the development of efficient catalysts: a momentary dissociation of the heteroatom from the

metal during a catalytic cycle releases a coordination site and allows the coordination of the substrate, while preserving the stability of the metal complex with the coordination of the NHC ligand. Several studies on the catalytic activity of NHC-SR metal complexes were reported in literature, including aldehyde hydrosilylation,^[18] Suzuki-Miyaura cross-coupling reaction^[19] and double bond hydrogenation.^[20]

Another interesting application of thioether-functionalized NHC metal complexes might be in the field of medicinal chemistry as anticancer drugs.^[21] Indeed, before reaching the targeting cells, the metal complexes might react with biological sulfur-containing molecules, for instance glutathione (GSH), causing a reduction in the activity towards cancer cells and development of undesired side effects.^[22] Thus, co-administration of a “chemoprotective agent”, such as S-containing oligopeptides, can significantly reduce the outbreak of side effects.^[23] Recently, studies on chemoprotective action and cytotoxic properties of sulfur-containing NHC ruthenium(II) and platinum(II) complexes have been reported by some of us.^[24,25] We decided to expand the scope of the metal complexes with such type of ligands and in this paper, we report on the synthesis, characterization and the preliminary antiproliferative results of gold(I) and gold(III) complexes bearing thioether-functionalized NHCs.

Chart 1. Examples of imidazolium salts bearing thioether functions.

Results and Discussion

The imidazolium salts used in this study are depicted in Chart 2 and their synthesis and characterization were recently reported by some of us.^[24,25]

- a, R = Bn, R1 = Ph, X = Cl
 b, R = Bn, R1 = p-C₆H₄-OMe, X = Br
 c, R = Bn, R1 = p-C₆H₄-Br, X = Br
 d, R = Bn, R1 = Et, X = Br
 e, R = Bn, R1 = Cy, X = Br
 f, R = Me, R1 = p-C₆H₄-Br, X = Br

Chart 2. Molecular structure of NHC-SR azolium salts used in this work.

Synthesis of the gold(I) complexes

The gold(I) complexes can be isolated through two different synthetic procedures: i) synthesis of the corresponding silver(I) complex by reaction of the imidazolium salt with Ag₂O, followed by transmetalation of the carbene ligand to the gold(I) centre using AuCl(SMe₂) as gold precursor (Scheme 1),^[26] or ii) metalation of the carbene with potassium carbonate and in the presence of the gold(I) precursor (Scheme 2).^[27] In both ways, complexes of general formula AuX(NHC-SR) (X=Cl or Br) can be isolated. Considering that the second procedure requires a single synthetic step and also the purification from the inorganic salts, formed as by-products, is easier, the majority of the synthesis has been performed with the weak base approach (See experimental section for details).

The formation of the silver(I) complexes **1** and **2** has been confirmed in the ¹H NMR spectra by the disappearance of the signal associated to the C2-H hydrogen; furthermore, in the ¹³C NMR spectra, the signal of the carbene coordinated to the silver centre is clearly identifiable at δ 180 ppm, in the typical range of carbene carbons bonded to silver centers.^[28] Finally, the ESI-MS spectra present a peak at *m/z* 757.09 and 854.89 for **1** and **2**, respectively, which can be associated to the bis-carbene species [Ag(NHC)₂]⁺. This is not surprising, because it is well known that the silver complexes of general formula AgX(NHC),

generally isolated in chlorinated solvents, can be involved in dynamic equilibria in solution, like $2 [\text{AgX}(\text{NHC})] \rightleftharpoons [\text{Ag}(\text{NHC})_2][\text{AgX}_2]$.^[29,30]

The gold(I) complex **3** was isolated via the transmetalation procedure, reacting the silver(I) complex **2** with AuCl(SMe₂) in 1:1 ratio. The NMR spectra of silver(I) and gold(I) complexes do not present significant differences in the number, pattern and position of signals, with the exception of the carbene carbon chemical shift (δ 182.1 ppm for **2** and δ 171.4 ppm for **3**). The evidence of the successful formation of the gold(I) complex derives mainly from the ESI mass spectra, which present a signal at *m/z* 942.99, associable to [Au(NHC)₂]⁺ fragment; also in this case, the formation of the cationic species occurs during the mass spectrometry experiment. In fact, the carbene carbon chemical shift most likely suggests for the gold(I) complex a structure of the type AuX(NHC) (X= halide), since in bis(carbene) species like [Au(NHC)₂]⁺ the carbene carbon chemical shift is usually shifted downfield, at around 180-185 ppm.^[31] Finally, complex **3** was unambiguously characterized by X-ray diffraction analysis (*vide infra*).

Gold(I) complexes **4-9** were synthesized through concerted metalation deprotonation mechanism starting directly from the imidazolium salts.^[32] The reaction proceeds in acetonitrile in presence of a large excess of K₂CO₃ as base (10 equivalents), a slight excess of gold precursor AuCl(SMe₂) and eventually the addition of LiBr. The successful coordination of the carbene to the gold(I) centre was confirmed by the disappearance in the ¹H NMR spectra of the signal around 8.7 ppm assigned to the acidic C2-H of the imidazolium, and also by the presence in the ¹³C NMR spectra of a signal around 171-175 ppm, assigned to the coordinated carbene carbon, in agreement with literature values.^[33]

Suitable crystals for X-ray structure analysis of complexes **3** and **9** have been obtained by slow diffusion of diethyl ether into an acetonitrile solution of the proper complex. The obtained molecular structures are displayed in Figures 1 and 2, together with selected bond distances (Å) and angles (°). Both structures show the expected atom connectivity with the gold(I) centres almost linearly dicoordinated by an NHC donor and a halide *trans* to each other. Bond distances and angles agree with literature data for similar gold(I) NHC complexes.^[30,34]

Scheme 1. Synthesis of silver(I) and gold(I) complexes **1-3**.

- 4, R = Bn, R¹ = Ph, X = Cl
 5, R = Bn, R¹ = p-C₆H₄-OMe, X = Br
 6, R = Bn, R¹ = p-C₆H₄-Br, X = Br
 7, R = Bn, R¹ = Et, X = Br
 8, R = Bn, R¹ = Cy, X = Br
 9, R = Me, R¹ = p-C₆H₄-Br, X = Br

Scheme 2. Synthesis of the gold(I) complexes 4-9.

Figure 1. ORTEP view of compound **3**, evidencing the dimeric structure build up through interactions explained in the text. Ellipsoids are shown at 50% probability level. Hydrogen atoms are omitted for clarity. Selected bond distances (Å) and angles (°): Au1-C1 1.979(4), Au2-C19 1.970(5), Au1-Cl1 2.2948(10), Au2-Cl2 2.2923(10), C1-N1 1.355(5), C1-N2 1.357(5), C19-N3 1.345(5), C19-N4 1.367(5), S1-C12 1.798(4), S1-C13 1.767(4), S2-C30 1.803(4), S2-C31 1.766(4), C16-Br1 1.907(4), C34-Br2 1.904(5), C1-Au1-Cl1 176.59(12), C19-Au2-Cl2 177.33(12), N1-C1-N2 104.3(4), N3-C19-N4 104.1(4), C12-S1-C13 104.1(2), C30-S2-C31 104.4(2).

Figure 2. ORTEP view of compound **9**. Ellipsoids are shown at 50% probability level. Hydrogen atoms are omitted for clarity. Selected bond distances (Å) and angles (°): Au-C1 1.988(6), Au-Br2 2.3966(16), C1-N1

1.351(9), C1-N2 1.334(9), S-C6 1.786(8), S-C7 1.757(8), C10-Br1 1.912(8), C1-Au-Br2 177.72(18), N1-C1-N2 105.5(6), C6-S-C7 105.2(4).

Figure 3. Crystal packing of complex **9**. View along the *b* crystallographic axis.

In the molecular structure of complex **3**, two crystallographic independent complex molecules are found in the asymmetric unit, presenting almost identical structural features in terms of bond distances and angles (Figure 1). The two molecules are coupled together, as a consequence of the presence of three weak attractive intermolecular interactions. There are in fact: (i) a weak aurophilic interaction, with an Au1...Au2 distance of 3.7371(3) Å; (ii) a Cl...H-C interaction between the chlorine atoms and the methylene thioether protons (Cl1...H-C30 and Cl2...H-C12), and a π-π stacking interaction between the aromatic rings of the benzyl wingtip substituents of the two molecules (C5-C10 and C23-C28) contributing to the formation of the dimeric aggregate.

In the structure of complex **9**, the two mean planes defined by the NHC donor (C1, N1, C3, C4, N2) and by the six-membered aromatic ring (C7-C12) are almost parallel with an angle of 2.0(3)° between them. The complex thus presents a stretched out or pseudoplanar conformation. The crystal packing of compound **9** is shown in Figure 3. Complex molecules arrangement is driven by π-π interactions running along the crystallographic *a* axis. No intermolecular aurophilic interaction can be observed.

Synthesis of the gold(III) complexes

The procedure for the synthesis of gold(III) complexes consists in the oxidative addition of molecular bromine to the corresponding gold(I) complexes.^[33,35] The reaction is carried out in acetonitrile with 1.2 equivalent of Br₂ with respect to the gold(I) complex and the corresponding gold(III) complexes are isolated in excellent yields and without further purification steps (Scheme 3).

Scheme 3. Synthesis of the gold(III) complexes **10-13**.

The ^1H NMR spectra of the synthesized gold(III) complexes in deuterated acetonitrile are similar to those observed for the pristine gold(I) complexes, except for a slight downfield shift for all the signals. In contrast, the ^{13}C NMR spectra display a signal for the carbene carbon around δ 134-141 ppm, in agreement with the values reported in literature, but high-field shifted of ca. 40 ppm compared to the carbene carbon coordinated to a gold(I) centre.^[33,35-37] This difference is commonly attributed to an increased Lewis acidity of gold atom, which indicates some withdrawal of π -electron density from the carbon-carbon double bond to the carbene carbon, through the aromatic system of the heterocyclic ring.^[33] Another significant evidence of the successful oxidation came from the ESI-MS spectra, in which the signals related to the gold(III) complexes adducts with Na^+ or K^+ are observed.

The behaviour of complex **12** in deuterated chloroform differs from that recorded in deuterated acetonitrile. In particular, in the ^1H NMR spectra in deuterated chloroform, the signals of the CH_2 protons in α to the sulfur atom are completely absent and also

the remaining signals are broad and lacking an evident fine structure (Figure 4a). With the other three gold(III) complexes (**10**, **11** and **13**) this different behaviour in the ^1H NMR spectra is not observed when changing the deuterated solvent. Variable temperature ^1H NMR spectra were recorded for complex **12** in the range 223 - 323 K (Figure 4b) in order to obtain more information on the possible dynamic processes of the complex: at temperatures lower than 273 K the two signals of the methylene protons in α position to the sulfur atom gradually become visible. The same behaviour is also observed by increasing the temperature up to 323 K. Either increasing or decreasing the temperature, the initial spectrum could be restored, when back to room temperature. This fluxional behaviour suggests that in chloroform a weak coordination of the thioether moiety to the gold centre can occur.^[24,38]

Finally, it was also possible to obtain few crystals of the complexes **10**, **11** and **13**, suitable for single crystal XRD analysis by slow evaporation of acetonitrile solution of the proper complex. The molecular structures of the three complexes are reported in Figure 5.

In these molecular structures, the gold atom adopts a square planar geometry as expected for d^8 electronic configuration metals, with $\text{C-Au-Br}_{\text{trans}}$ and $\text{Br-Au-Br}_{\text{trans}}$ angles close to linearity. The mean plane defined by the NHC ring (N1-C1-N2-C2-C3) is almost perpendicular with respect to the gold(III) mean coordination plane; the angle between the two planes is $76.68(15)^\circ$ in **10**, $83.19(19)^\circ$ in **11** and $73.71(16)^\circ$ in **13**, in good agreement with the values reported in literature for $[\text{AuBr}_3(\text{NHC})]$ complexes.^[33]

Figure 4. a) ^1H NMR spectra of complex **12** in CD_3CN and CDCl_3 . b) Variable temperature ^1H NMR spectra of complex **12** in CDCl_3 .

Figure 5. ORTEP view of compounds **10** (top left), **11** (top right) and **13** (bottom). Ellipsoids are shown at 50% probability level. Hydrogen atoms are omitted for clarity. Selected bond distances (Å) and angles (°): **10**. Au-C1 2.019(4), Au-Br1 2.4185(5), Au-Br2 2.4434(5), Au-Br3 2.4115(6), C1-N1 1.351(5), C1-N2 1.327(5), S-C12 1.800(5), S-C13 1.765(5), O-C16 1.369(7), O-C19 1.433(9), C1-Au-Br1 90.42(12), C1-Au-Br2 176.37(12), C1-Au-Br3 87.32(12), Br3-Au-Br1 176.98(2), N1-C1-N2 106.5(4), C12-S-C13 102.6(2), C16-O-C19 118.0(6). **11**. Au-C1 2.004(5), Au-Br2 2.4107(7), Au-Br3 2.4471(6), Au-Br4 2.4165(6), C1-N1 1.336(7), C1-N2 1.326(7), S-C12 1.803(6), S-C13 1.773(7), C16-Br1 1.904(6), C1-Au-Br3 177.75(15), Br2-Au-Br4 175.66(2), C1-Au-Br2 88.84(15), C1-Au-Br4 86.93(15), N1-C1-N2 107.0(4), C12-S-C13 103.7(3). **13**. Au-C1 2.006(6), Au-Br1 2.4287(7), Au-Br2 2.4406(7), Au-Br3 2.4110(7), C1-N1 1.342(7), C1-N2 1.344(7), S-C5 1.815(6), S-C6 1.825(5), C1-Au-Br1 90.25(14), C1-Au-Br2 176.19(14), C1-Au-Br3 86.77(14), Br3-Au-Br1 176.87(2), N1-C1-N2 106.7(5), C5-S-C6 101.3(3).

Figure 6. Elemental crystallographic cell of complex **10** (left) and **11** (right), with highlighted Br...C short contacts. Symmetry code $i = 1-x, 1-y, 1-z$.

In the unit cell of complexes **10** and **11**, two molecules of the complex form a dimeric unit, through mutual interactions between a Br ligand *cis* with respect to the NHC donor and the NHC carbon-carbon double bond of the paired molecule. The Br...C distances span from 3.41 to 3.54 Å (Figure 6). In general, the interactions between one coordinated Br atom and the π -electron density of the NHC carbon-carbon double bond of another complex molecule are common in the solid state of monocarbene gold(III) complexes.^[33,39] This type of interaction is not present in the unit cell of complex **13**.

DFT calculations

The difference observed in the behaviour in chloroform and acetonitrile solution of complexes **10-12** has been further investigated by DFT calculations. In particular, in order to simplify the structure and considering the similarity of complexes **10** and **11**, an unsubstituted phenyl ring bonded to the sulphur atom. The structure of complexes $\text{AuBr}_3(\text{B}^{\text{n}}\text{Im}^{\text{Et}})$ **12** and the simplified complex $\text{AuBr}_3(\text{B}^{\text{n}}\text{Im}^{\text{Ph}})$ have been fully optimised at ZORA-BLYP-D3(BJ)/TZ2P level of theory. The optimised geometry of this last complex is in very good agreement with the crystallographic structures reported for **10** and **11** having a *para*-substituted phenyl ring.

In addition, we have explored the chelation of the sulfur atom of the NHC ligand leading to the cationic complex $\text{cis}[\text{AuBr}_2(\kappa^2\text{-C,S-NHC})]^+$. The formation of this species might be in fact responsible for the differences appearing in the NMR spectra. The structures of these cations have been fully optimized at ZORA-BLYP-D3(BJ)/TZ2P level as well. From the single point energies computed in gas phase and in condensed phase, i.e. acetonitrile and chloroform, we estimated the ΔE_r of the reaction:

In gas phase, the reaction energy ΔE_r is 107.64 kcal mol⁻¹ and 109.77 kcal mol⁻¹ for the ethyl and phenyl substituted compounds, respectively. These values decrease but remain positive when chloroform or acetonitrile are used as solvents (24.69 kcal mol⁻¹ and 27.39 kcal mol⁻¹ in chloroform, 4.53 kcal mol⁻¹ and 7.27 kcal mol⁻¹ in acetonitrile, for **12** and the model compound with the phenyl substituent, respectively). The positive reaction energy agrees with the experimental findings, i.e. all the complexes are isolated as neutral species, without chelation of the sulphur atom. Furthermore, if chelation occurred, the ¹H NMR spectrum of the formed complex would be more complicated than the one observed for complex **12**, due to the presence of diastereotopic CH₂ groups.

These results are also supported by an in depth study on the possible processes converting the species $\text{cis}[\text{AuBr}_2(\kappa^2\text{-C,S-NHC})]^+$ into the neutral complex $[\text{AuBr}_3(\kappa^1\text{-C-NHC})]$ focusing on two possible pathways: (i) a two-step process involving sulfur dissociation followed by bromide coordination and (ii) concerted mechanism with bromide attacking the gold centre via a square pyramid transition state. The dissociative mechanism can be ruled out because the three-coordinated $[\text{AuBr}_2(\kappa^1\text{-C-NHC})]^+$ is too destabilized.^[40]

For the concerted pathway, a linear scan of the PES (potential energy surface) was carried out letting Br⁻ approach to the Au centre along a direction approximately orthogonal to the ring plane. In gas phase, a slightly stabilised reactant complex initially forms (the minimum at Au-S distance 2.4-2.5 Å in Figure

7), which, through a modest energy barrier for Au-S bond cleavage (4.7 and 6.4 kcal mol⁻¹, for the complexes $[\text{AuBr}_2(\kappa^2\text{-C,S-NHC})]^+$ with ethyl or phenyl sulphur substituent respectively), is converted into the tribromo complex $[\text{AuBr}_3(\kappa^1\text{-C-NHC})]$ (Figure 7).^[41]

These data represent also an incidental proof that the interaction of the sulphur donor with the gold(III) centre is more favoured when alkyl substituents rather than aryl ones are present.

As a whole, these data suggest that the marked behaviour observed for complex **12** compared to the other synthesised gold(III) complexes cannot be ascribed to a $\kappa^2\text{-C,S-NHC}$ ligand coordination, involving dissociation of a bromide anion and formation of a cyclic rigid moiety. Nonetheless, the ligand in the $[\text{AuBr}_3(\kappa^1\text{-C-NHC})]$ complex **12** has a remarkable conformational freedom and flexibility, so that the dynamic processes in solution might induce the establishment of a weak interaction between the sulfur atom and the gold(III) centre in the apical position. This interaction with the other complexes (**10**, **11** and **13**) is a negligible possibility for the greater steric hindrance of the sulfur substituent. Similar apical weak interactions, although uncommon, are already known for gold(III) complexes with NHCs having a nitrogen donor function on the side-arm of the heterocyclic carbene ring.^[42,43]

Figure 7. Linear PES scan: energy versus Au-S distance for complex $[\text{AuBr}_2(\kappa^2\text{-C,S-NHC})]^+$ with ethyl (black) or phenyl (red) sulphur substituent. Level of theory: ZORA-BLYP-D3(BJ)/TZ2P.

Cytotoxic properties of the gold(I) and gold(III) complexes

Finally, the antiproliferative activity of the synthesized gold(I) and gold(III) was evaluated against the MCF7 cancer cell line (breast cancer), and *cisplatin* was used as reference for the studies. The half inhibitory concentrations (IC₅₀ in μM) values induced by these complexes are displayed in Table 1.

All of the tested gold(I/III) complexes show antiproliferative activity, with IC₅₀ values comparable to that measured for the well-known anti-cancer drug *cisplatin* or for the analogous unfunctionalised Au(I) complex $[\text{AuCl}(\text{MeImMe})]$ with the 1,3-dimethylimidazol-2-ylidene ligand^[44] or other $\text{AuCl}(\text{NHC})$ complexes.^[45] Notably, the IC₅₀ values do not vary significantly from gold(I) to gold(III) complexes; this is not surprising considering that it is well known that gold(III) complexes could

be reduced in biological environment giving the corresponding gold(I) species.^[46–48] For this reason, we have studied by *in situ* NMR the reactivity of the gold(III) complexes **10** (Figure S30 in Supporting Information) and **11** with reduced glutathione (GSH), a very abundant tripeptide in the cells. We noticed that the gold(III) complexes react quickly with GSH in a DMSO-*d*₆/D₂O (1/1) mixture in few seconds affording the gold(I) complexes and the glutathione disulphide (GSSG).

Table 1. Half-inhibitory concentrations IC₅₀ (in μ M) values against MCF7 cancer cells for selected gold(I) and gold(III) complexes^[a]

Complex	IC ₅₀ (in μ M)
3 [AuCl(B ⁿ Im ^{Ph} Br)]	6.06 $\pm$ 0.86
5 [AuBr(B ⁿ Im ^{Ph} OMe)]	7.2 $\pm$ 0.3
6 [AuBr(B ⁿ Im ^{Ph} Br)]	14.4 $\pm$ 2.9
8 [AuBr(B ⁿ Im ^{Cy})]	3.98 $\pm$ 0.58
9 [AuBr(^{Me} Im ^{Ph} Br)]	9.12 $\pm$ 0.03
10 [AuBr ₃ (B ⁿ Im ^{Ph} OMe)]	13.7 $\pm$ 2.6
11 [AuBr ₃ (B ⁿ Im ^{Ph} Br)]	11.6 $\pm$ 0.9
<i>cisplatin</i>	11.9 $\pm$ 0.7
[AuCl(^{Me} Im ^{Me})] ^[b, c]	15 $\pm$ 4

[a] After 72h of incubation; stock solutions in DMSO for all complexes; stock solutions in H₂O for *cisplatin*. [b] ^{Me}Im^{Me} = 1,3-dimethylimidazol-2-ylidene. [c] from ref. 44.

Conclusion

A series of gold(I) complexes of general formula [AuX(NHC)] based on thioether-functionalized NHC ligands have been synthesized by base-assisted metalation and fully characterized, both in solution and in the solid state. The corresponding gold(III) complexes [AuBr₃(NHC)] were isolated straightforwardly by oxidative addition of bromine to the gold(I) centres. The NHC behaves as a monodentate κ^1 -C ligand, although with the small ethyl group as substituent on the sulfur atom there are some evidences of a sulfur interaction with the gold centre. The potential chelation of the ligand has been also investigated by means of relativistic DFT calculations.

The complexes displayed moderate antiproliferative activity, without a marked difference between gold(I) and gold(III) species, as expected considering that gold(III) can be reduced by the thiol-functionalized molecules present in the cell.

Experimental Section

Materials and methods

Reagents were purchased from Sigma-Aldrich as high-purity products and used as received. All manipulations were carried out using standard Schlenk techniques under an atmosphere of argon. NMR spectra were recorded on a Bruker Avance 300 MHz operating at 300.1 MHz for ¹H and 75.5 MHz for ¹³C; chemical shifts (δ) are reported in units of ppm relative to the residual solvent signals. ESI-MS analyses were performed

using a Thermo-Finnigan LCQ-Duo operating in positive ion mode; sample solutions were prepared by dissolving the compounds in acetonitrile and were directly infused into the ESI source by a syringe pump. Elemental analysis were carried out with a Thermo Scientific FLASH 2000 apparatus. The imidazolium salts were prepared following published procedures.^[24,25]

Synthesis of the silver(I) complexes **1** and **2**

The proper imidazolium salt (0.25 mmol) and Ag₂O (0.25 mmol) were placed in a two neck round bottom flask. Subsequently, under inert atmosphere, CH₂Cl₂ (10–20 mL) was added and the reaction mixture was left under stirring for 24 hours at room temperature with the exclusion of light. Afterwards, it was filtered with a syringe using a PTFE 0.45 μ m filter. The volatiles were removed under vacuum and addition of n-hexane gave the desired complex as a light grey solid, which was filtered and dried under vacuum.

Complex [AgBr(BⁿIm^{Ph}OMe)] **1**. ¹H NMR (CD₃CN) δ 7.50 – 7.10 (m, 9H, Ar), 6.79 (s, 1H, CH), 6.76 (s, 1H, CH), 5.22 (s, 2H, NCH₂Ph), 4.19 (t, J = 6.6 Hz, 2H, NCH₂), 3.71 (s, 3H, CH₃), 3.22 (t, J = 6.6 Hz, 2H, CH₂S). ¹³C NMR (CD₃CN) δ 182.1 (C_NCN), 160.0 (Ar), 137.9 (Ar), 133.8 (Ar), 129.8 (Ar), 129.1 (Ar), 128.7 (Ar), 125.4 (Ar), 122.8 (CH), 122.7 (CH), 115.8 (Ar), 56.0 (CH₃), 55.7 (CH₂Ph), 51.7 (CH₂N), 36.9 (CH₂S). ESI-MS *m/z* (%): 757.09 (100) [Ag(BⁿIm^{Ph}OMe)₂]⁺.

Complex [AgBr(BⁿIm^{Ph}Br)] **2**. ¹H NMR (CD₃CN) δ 7.50 – 7.10 (m, 11H, Ar), 5.18 (s, 2H, CH₂Ph), 4.25 (t, J = 6.5 Hz, 2H, NCH₂), 3.34 (t, J = 6.5 Hz, 2H, CH₂S). ¹³C NMR (CD₃CN) δ 181.4 (C_NCN), 137.8 (Ar), 135.2 (Ar), 133.0 (Ar), 131.4 (Ar), 129.8 (Ar), 129.2 (Ar), 128.6 (Ar), 123.0 (CH), 122.8 (CH), 120.4 (Ar), 55.7 (CH₂Ph), 51.5 (NCH₂), 34.7 (CH₂S). ESI-MS *m/z* (%): 854.89 (100) [Ag(BⁿIm^{Ph}Br)₂]⁺.

Synthesis of the gold(I) complex **3** via transmetalation reaction

AuCl(SMe₂) (65 mg, 0.22 mmol) was added to a solution of silver(I) complex **2** (125 mg, 0.22 mmol) in CH₃CN (15 mL). The reaction mixture was left under stirring for 4 hours at room temperature; afterwards, it was filtered with a syringe using a PTFE 0.45 μ m filter and the solvent was removed under vacuum in order to isolate a white solid. Yield 66 %. ¹H NMR (CD₃CN) δ 7.50 – 7.22 (m, 9H, Ar), 7.15 (d, J = 2.0 Hz, 1H, CH), 7.10 (d, J = 2.0 Hz, 1H, CH), 5.31 (s, 2H, CH₂Ph), 4.34 (t, J = 6.8 Hz, 2H, NCH₂), 3.42 (t, J = 6.8 Hz, 2H, CH₂S). ¹³C NMR (CD₃CN) δ 171.3 (C_NCN), 137.4 (Ar), 135.1 (Ar), 133.0 (Ar), 131.6 (Ar), 129.8 (Ar), 129.2 (Ar), 128.6 (Ar), 122.8 (CH), 122.2 (CH), 120.4 (Ar), 55.3 (CH₂Ph), 51.1 (NCH₂), 34.2 (CH₂S). ESI-MS *m/z* (%): 1174.72 (20) [Au₂Cl(BⁿIm^{Ph}Br)₂]⁺, 942.99 (100) [Au(BⁿIm^{Ph}Br)₂]⁺.

Synthesis of the gold(I) complexes via deprotonation of the imidazolium salt: synthesis of complexes **4–9**

The proper imidazolium salt (1 equiv.), AuCl(SMe₂) (1.05 equiv.) and K₂CO₃ (10 equiv.) were placed in a two neck round bottom flask. Subsequently, under inert atmosphere, CH₃CN (10–20 mL) was added and the reaction mixture was left under stirring for 10 hours at room temperature with the exclusion of light. Afterwards, it was filtered with a syringe using a PTFE 0.45 μ m filter. The volatiles were removed under vacuum and addition of n-hexane gave the desired complex as a light grey solid, which was filtered and dried under vacuum.

Complex [AuCl(BⁿIm^{Ph})] **4**. Yield 86%. ¹H NMR (CD₃CN) δ 7.52 – 7.00 (m, 12H, Ar), 5.30 (s, 2H, CH₂Ph), 4.31 (t, J = 6.9 Hz, 2H, NCH₂), 3.40 (t, J = 6.9 Hz, 2H, CH₂S). ¹³C NMR (CD₃CN) δ 171.2 (C_NCN), 137.3 (Ar), 135.5 (Ar), 130.2 (Ar), 129.9 (Ar), 129.8 (Ar), 129.2 (Ar), 128.6 (Ar), 127.3 (Ar), 122.9 (CH), 122.2 (CH), 55.3 (CH₂Ph), 51.2 (NCH₂), 34.4 (CH₂S). ESI-MS *m/z* (%): 785.17 (100) [Au(BⁿIm^{Ph})₂]⁺.

Complex [AuBr(BⁿIm^{Ph}OMe)] **5**. Yield 95%. ¹H NMR (CD₃CN) δ 7.50 – 7.27 (m, 7H, Ar), 7.15–7.10 (m, 2H, Ar), 6.90 (m, 1H, CH), 6.87 (m, 1H, CH), 5.33 (s, 2H, CH₂Ph), 4.30 (t, J = 6.8 Hz, 2H, NCH₂), 3.78 (s, 3H, CH₃), 3.32 (t, J = 6.8 Hz, 2H, CH₂S). ¹³C NMR (CD₃CN) δ 174.6 (C_NCN), 160.1 (Ar), 137.4 (Ar), 134.0 (Ar), 129.8 (Ar), 129.2 (Ar), 128.6 (Ar), 125.3 (Ar), 122.6 (CH), 122.1 (CH), 115.9 (Ar), 56.0 (CH₃), 55.2 (CH₂Ph), 51.2 (NCH₂), 36.3 (CH₂S). ESI-MS *m/z* (%): 845.18 (100) [Au(BⁿIm^{Ph}OMe)₂]⁺.

Complex [AuBr(BⁿIm^{Ph}Br)] **6**. Yield 72%. ¹H NMR (CD₃CN) δ 7.57 – 7.22 (m, 9H, Ar), 7.16 (d, J = 2.0 Hz, 1H, CH), 7.11 (d, J = 2.0 Hz, 1H, CH),

5.32 (s, 2H, CH₂Ph), 4.35 (t, J = 6.8 Hz, 2H, NCH₂), 3.42 (t, J = 6.8 Hz, 2H, CH₂S). ¹³C NMR (CD₃CN) δ 174.6 (C_NCN), 137.3 (Ar), 135.1 (Ar), 133.1 (Ar), 131.6 (Ar), 129.8 (Ar), 129.2 (Ar), 128.6 (Ar), 122.7 (CH), 122.2 (CH), 120.4 (Ar), 55.2 (CH₂Ph), 50.9 (NCH₂), 34.2 (CH₂S). ESI-MS *m/z* (%): 1174.72 (20) [Au₂Cl(B^{Br}Im^{PhBr})₂]⁺, 942.99 (100) [Au(B^{Br}Im^{PhBr})₂]⁺.

Complex [AuBr(B^{Br}Im^{Et})] **7**. Yield 72%. ¹H NMR (CD₃CN) δ 7.36 (m, 5H, Ar), 7.22 (d, J = 1.9 Hz, 1H, CH), 7.17 (d, J = 1.9 Hz, 1H, CH), 5.36 (s, 2H, CH₂Ph), 4.38 (t, J = 6.8 Hz, 2H, NCH₂), 3.09 (br, 2H, CH₂S), 2.67 (br, 2H, CH₂), 1.23 (t, J = 7.4 Hz, 3H, CH₃). ¹H NMR (CDCl₃) δ 7.31 (m, 5H, Ar), 7.06 (d, J = 1.9 Hz, 1H, CH), 6.88 (d, J = 1.9 Hz, 1H, CH), 5.33 (s, 2H, CH₂Ph), 4.31 (t, J = 6.8 Hz, 2H, NCH₂), 2.96 (t, J = 6.8 Hz, 2H, CH₂S), 2.51 (q, J = 7.4 Hz, 2H, CH₂), 1.21 (t, J = 7.4 Hz, 3H, CH₃). ¹³C NMR (CDCl₃) δ 174.1 (C_NCN), 135.0 (Ar), 129.1 (Ar), 128.7 (Ar), 128.0 (Ar), 121.8 (CH), 120.3 (CH), 55.1 (CH₂Ph), 50.8 (NCH₂), 32.5 (CH₂S), 26.3 (CH₂), 14.8 (CH₃). ESI-MS *m/z* (%): 689.20 (100) [Au(B^{Br}Im^{Et})₂]⁺.

Complex [AuBr(B^{Br}Im^{Cy})] **8**. Yield 84%. ¹H NMR (CD₃CN) δ 7.36 (m, 5H, Ar), 7.20 (d, J = 1.9 Hz, 1H, CH), 7.17 (d, J = 1.9 Hz, 1H, CH), 5.36 (s, 2H, CH₂Ph), 4.32 (t, J = 6.9 Hz, 2H, NCH₂), 2.98 (t, J = 6.9 Hz, 2H, CH₂S), 2.85 – 2.64 (m, 1H, CH Cy), 1.75 – 1.12 (m, 10H, CH₂ Cy). ¹³C NMR (CD₃CN) δ 174.7 (C_NCN), 137.5 (Ar), 129.8 (Ar), 129.2 (Ar), 128.6 (Ar), 122.7 (CH), 122.1 (CH), 55.2 (CH₂Ph), 51.7 (NCH₂), 43.5 (CHS), 34.4 (CH₂ Cy), 31.0 (CH₂S), 26.7 (CH₂ Cy), 26.4 (CH₂ Cy). ESI-MS *m/z* (%): 797.28 (100) [Au(B^{Br}Im^{Cy})₂]⁺.

Complex [AuBr(M^{Br}Im^{PhBr})] **9**. Yield 75%. ¹H NMR (CD₃CN) δ 7.50 – 7.25 (2m, 4H, Ar), 7.11 (d, J = 1.8 Hz, 1H, CH), 7.03 (d, J = 1.8 Hz, 1H, CH), 4.31 (t, J = 6.9 Hz, 2H, NCH₂N), 3.72 (s, 3H, CH₃), 3.40 (t, J = 6.9 Hz, 2H, CH₂S). ¹³C NMR (CD₃CN) δ 174.7 (C_NCN), 135.1 (Ar), 133.0 (Ar), 131.8 (Ar), 123.3 (CH), 122.1 (CH), 120.5 (Ar), 50.9 (NCH₂), 38.5 (CH₃), 34.3 (CH₂S). ESI-MS *m/z* (%): 790.91 (100) [Au(M^{Br}Im^{PhBr})₂]⁺.

Synthesis of the gold(III) complexes via oxidative addition of bromine: synthesis of complexes 10-13

A solution of bromine in acetonitrile was added to a solution of the proper gold(I) complex in acetonitrile (ca. 10 mL) using a Au:Br₂ ratio 1:1.5. The reaction mixture was left under stirring for 2 hours at room temperature. Afterwards, the volatiles were removed under vacuum and addition of n-hexane gave the desired complex as a yellow solid, which was filtered and dried under vacuum.

Complex [AuBr₃(B^{Br}Im^{PhOMe})] **10**. Yield 91%. ¹H NMR (CD₃CN) δ 7.50 – 7.25 (m, 10H, Ar), 6.95–6.90 (m, 2H, CH), 5.39 (s, 2H, CH₂Ph), 4.34 (t, J = 6.7 Hz, 2H, NCH₂), 3.79 (s, 3H, CH₃), 3.36 (t, J = 6.7 Hz, 2H, CH₂S). ¹³C NMR (CD₃CN) δ 160.0 (Ar), 137.6 (Ar), 134.4 (C_NCN), 134.0 (Ar), 129.6 (Ar), 129.5 (2 Ar), 125.9 (CH), 125.1 (CH), 124.0 (Ar), 115.7 (Ar), 55.9 (CH₃), 54.9 (CH₂Ph), 50.7 (NCH₂), 34.7 (CH₂S). ESI-MS *m/z* (%): 1004.99 (66) [AuBr₂(B^{Br}Im^{PhOMe})₂]⁺, 845.25 (92) [Au(B^{Br}Im^{PhOMe})₂]⁺, 800.71 (40) [AuBr₃(B^{Br}Im^{PhOMe})]K⁺, 784.62 (100) [AuBr₃(B^{Br}Im^{PhOMe})]Na⁺, 680.80 (93) [AuBr₂(B^{Br}Im^{PhOMe})₂]⁺.

Complex [AuBr₃(B^{Br}Im^{PhBr})] **11**. Yield 92%. ¹H NMR (CD₃CN) δ 7.53 – 7.25 (m, 11H, Ar), 5.40 (s, 2H, CH₂Ph), 4.39 (t, J = 7.0 Hz, 2H, NCH₂), 3.48 (t, J = 7.0 Hz, 2H, CH₂S). ¹³C NMR (CDCl₃) δ 141.0 (C_NCN), 132.9 (Ar), 132.5 (Ar), 132.3 (Ar), 131.5 (Ar), 129.9 (Ar), 129.7 (Ar), 129.4 (Ar), 124.5 (CH), 122.9 (CH), 121.5 (Ar), 55.2 (CH₂Ph), 50.3 (CH₂), 33.3 (CH₂S). ESI-MS *m/z* (%): 1102.79 (35) [AuBr₂(B^{Br}Im^{PhBr})₂]⁺, 848.63 (17) [AuBr₃(B^{Br}Im^{PhBr})]K⁺, 832.57 (12) [AuBr₃(B^{Br}Im^{PhBr})]Na⁺, 730.67 (8) [AuBr₂(B^{Br}Im^{PhBr})₂]⁺.

Complex [AuBr₃(B^{Br}Im^{Et})] **12**. Yield 90%. ¹H NMR (CD₃CN) δ 7.47 (d, J = 2.0 Hz, 1H, CH), 7.44 – 7.38 (m, 5H, Ar), 7.32 (d, J = 2.0 Hz, 1H, CH), 5.42 (s, 2H, CH₂Ph), 4.41 (t, J = 7.0 Hz, 2H, NCH₂), 3.07 (t, J = 7.0 Hz, 2H, CH₂S), 2.59 (q, J = 7.3 Hz, 2H, CH₂), 1.24 (t, J = 7.3 Hz, 3H, CH₃). ¹H NMR (CDCl₃) δ 7.38–7.26 (m, 6H, Ar and CH), 6.96 (s, 1H, CH), 5.36 (s, 2H, CH₂Ph), 4.39 (t, J = 7.0 Hz, 2H, NCH₂), 1.25 (t, J = 7.3 Hz, 3H, CH₃), the two CH₂S are not visible. ¹³C NMR (CD₃CN) δ 138.0 (Ar), 134.9 (C_NCN), 130.0 (Ar), 129.9 (2 Ar), 126.1 (CH), 125.2 (CH), 55.2 (CH₂Ph), 51.5 (NCH₂), 31.3 (CH₂S), 26.5 (CH₂), 15.3 (CH₃). ESI-MS (CH₃CN) *m/z* (%): 848.90 (100) [Au(B^{Br}Im^{Et})₂]⁺, 602.78 (40) [Au(B^{Br}Im^{Et})Br₂]⁺.

Complex [AuBr₃(B^{Br}Im^{Cy})] **13**. Yield 85%. ¹H NMR (CD₃CN) δ 7.47 (d, J = 2.0 Hz, 1H, CH), 7.40 (bs, 5H, Ar), 7.30 (d, J = 2.0 Hz, 1H, CH), 5.42 (s, 2H, CH₂Ph), 4.39 (t, J = 7.2 Hz, 2H, NCH₂), 3.06 (t, J = 7.2 Hz, 2H, CH₂S),

2.75 – 2.60 (m, 1H, CH Cy), 1.75 – 1.12 (m, 10H, CH₂ Cy). ¹H NMR (CDCl₃) δ 7.42 (br, 5H, Ar), 7.29 (s, 1H, CH), 6.94 (s, 1H, CH), 5.39 (s, 2H, CH₂Ph), 4.43 (t, J = 7.2 Hz, 2H, NCH₂), 3.16 (br, 2H, CH₂S), 2.75 – 2.60 (br, 1H, CH Cy), 1.80 – 1.20 (m, 10H, CH₂ Cy). ¹³C NMR (CD₃CN) δ 137.9 (Ar), 134.9 (C_NCN), 130.0 (Ar), 129.9 (2 Ar), 126.1 (CH), 125.0 (CH), 55.2 (CH₂Ph), 52.2 (NCH₂), 44.0 (CHS), 34.7 (CH₂ Cy), 29.6 (CH₂S), 26.8 (CH₂ Cy), 26.3 (CH₂ Cy). ESI-MS (CH₃CN) *m/z* (%): 957.04 (100) [AuBr₂(B^{Br}Im^{Cy})₂]⁺.

Biological results

Cytotoxicity tests have been carried out at the "Institut de Chimie des Substances Naturelles CNRS - UPR2301, Gif-Sur-Yvette, France". Samples were prepared by dissolution of the compounds in DMSO except for *cisplatin* (used as reference) that was dissolved in water at stock concentrations of 10 mM. MCF7 (breast cancer cells) cell line was maintained as monolayers in RPMI 1640 medium supplemented with 10% fetal calf serum, in the presence of penicilline, streptomycine and fungizone in 75 cm² flask under 5% CO₂. Cells were plated in 96-well tissue culture plates in 200 µl complete medium at a density of 1000–2500 cells per well and treated 24 h later with 2 µl of compounds using a Biomek 3000 automation workstation (Beckman-Coulter). Controls received the same volume of the appropriate vehicle (DMSO or water, 1% final volume). After 72 h exposure, MTS reagent (CellTiter 96® Aqueous One, Promega) was added and incubated for 3h at 37 °C: the absorbance was monitored at 90nm and results expressed as the inhibition of cell proliferation calculated as the ratio [(1-(OD490 reated/OD490 control))×100] in triplicate experiments after subtraction of the blank without cells. Positive controls (cells incubated with a reference drug at its IC50 concentration) were routinely added to check the responsiveness of cells. For IC50 determination [50% inhibition of cell proliferation], cells were incubated for 72 h following the same protocol with compound concentrations ranged 5 nM to 100 µM in separate duplicate experiments. At these concentrations, no interference with Pt or Au complexes was noticed at 490 nm. Values are given as means ± SD from at least three independent experiments performed in triplicate.

Reactivity test of NHC gold(III) complexes and glutathione (GSH)

Solutions of the NHC gold(III) complex (2 mM in DMSO-*d*₆, solution A) and GSH (4 mM in D₂O, solution B) have been prepared. The ¹H-NMR spectrum of GSH in DMSO-*d*₆/D₂O (1:1) and of the NHC-gold(III) complex in DMSO-*d*₆ have been recorded. Then, 0.5 mL of solution A + 0.5 mL of solution B have been mixed and the ¹H NMR spectrum has been recorded immediately after the mixing.

DFT calculations

Density Functional Theory (DFT) calculations were carried out with the Amsterdam Density Functional (ADF) software,^[49–52] using the BLYP^[53] functional corrected with the dispersion contribution term by Grimme et al.^[54] and employing the zeroth-order regular approximation (ZORA)^[55] to take into account relativistic effects, which are mandatory in the presence of heavy nuclei.^[56] The TZ2P basis set was used for all the elements. It is a large uncontracted set of Slater-type orbitals (STOs), is of triple-ζ quality and is augmented with two sets of polarization functions on each atom. In addition, core electrons were described with the frozen-core approximation: up to 1s for C, N, O and S, and up to 4d in the case of Au. For the numerical integration, the Becke grid was used.^[57,58] This level of theory, denoted ZORA-BLYP-D3(BJ)/TZ2P has already been employed with success in studies of the structural and electronic properties of Au(I) and Au(III) NHC complexes.^[59] Frequency calculations were carried out to assess the nature of the stationary points. Solvent effects were taken into account with the Conductor-like Screening Model (COSMO),^[60,61] which is implemented in the ADF program. For acetonitrile and chloroform, we used a solvent-excluding surface with an effective radius of 2.76 Å and 3.17 Å, and a relative dielectric constant of 37.5 and 4.8, respectively. The empirical parameter in the scaling function in the COSMO equation was set to 0.0. The radii of the atoms were taken to be MM3 radii,^[62] divided by 1.2, giving 1.350 Å for H, 1.700 Å for C, 1.608 Å for N, 1.517 Å for O, 1.792 Å for S and 2.025 Å for Au.^[63]

Acknowledgements

CARIPARO Foundation (Excellence Project 2018 «SELECT») and Università degli Studi di Padova (P-DISC 2018, project MAD³S) are acknowledged for partial financial support to this research. M.B. thanks the DAAD (Short-Term Grants, 2018 (57378443)) for a scholarship. R.D.M. acknowledges the Erasmus+ traineeship program for a fellowship.

Keywords: Gold complexes • N-heterocyclic carbene ligands • cytotoxic activity • thioether groups • oxidative addition

- [1] S. Diez-Gonzalez, *N-Heterocyclic Carbenes: From Laboratory Curiosities to Efficient Synthetic Tools*, 2nd Edition, **2017**, Cambridge: RSC Catalysis Series, RSC.
- [2] S. P. Nolan, *N-Heterocyclic Carbenes, Effective Tools for Organometallic Synthesis*, Wiley-VCH, Weinheim, **2014**.
- [3] H. V. Huynh, *The organometallic chemistry of N-heterocyclic carbenes*, **2017**, Hoboken, NJ: John Wiley & Sons, Inc.
- [4] L. Benhamou, E. Chardon, G. Lavigne, S. Bellemin-Lapponnaz, V. César, *Chem. Rev.* **2011**, *111*, 2705–2733.
- [5] H. M. Lee, C.-C. Lee, P.-Y. Cheng, *Curr. Org. Chem.* **2007**, *11*, 1491 – 1524.
- [6] S. Hameury, P. de Frémont, P. Braunstein, *Chem. Soc. Rev.* **2017**, *46*, 632–733.
- [7] S. T. Liddle, I. S. Edworthy, P. L. Arnold, *Chem. Soc. Rev.* **2007**, *36*, 1732–1744.
- [8] R. E. Andrew, L. González-Sebastián, A. B. Chaplin, *Dalton Trans.* **2016**, *45*, 1299–1305.
- [9] D. Pugh, A. A. Danopoulos, *Coord. Chem. Rev.* **2007**, *251*, 610–641.
- [10] L. H. Gade, S. Bellemin-Lapponnaz, *Coord. Chem. Rev.* **2007**, *251*, 718–725.
- [11] E. Peris, *Chem. Rev.* **2018**, *118*, 9988–10031.
- [12] M. Bierenstiel, E. D. Cross, *Coord. Chem. Rev.* **2011**, *255*, 574–590.
- [13] D. Yuan, H. V. Huynh, *Molecules* **2012**, *17*, 2491–2517.
- [14] C. Fliedel, P. Braunstein, *J. Organomet. Chem.* **2014**, *751*, 286–300.
- [15] C. Fliedel, G. Schnee, P. Braunstein, *Dalton Trans.* **2009**, 2474–2476.
- [16] J. Wolf, A. Labande, J.-C. Daran, R. Poli, *Eur. J. Inorg. Chem.* **2007**, *2007*, 5069–5079.
- [17] A. Labande, J.-C. Daran, N. J. Long, A. J. P. White, R. Poli, *New J. Chem.* **2011**, *35*, 2162–2168.
- [18] F. Ulm, A. I. Poblador-Bahamonde, S. Choppin, S. Bellemin-Lapponnaz, M. J. Chetcuti, T. Achard, V. Ritleng, *Dalton Trans.* **2018**, *47*, 17134–17145.
- [19] K. N. Sharma, N. Satrawala, R. K. Joshi, *Eur. J. Inorg. Chem.* **2018**, *2018*, 1743–1751.
- [20] C. Gandolfi, M. Heckenroth, A. Neels, G. Laurenczy, M. Albrecht, *Organometallics* **2009**, *28*, 5112–5121.
- [21] a) S. Ftouh, S. Bourgeade-Delmas, M. Belkadi, C. Deraeve, C. Hemmert, A. Valentin, H. Gornitzka, *Organometallics* DOI 10.1021/acs.organomet.1c00113. b) C. Zhang, S. Bourgeade Delmas, A. Fernández Álvarez, A. Valentin, C. Hemmert, H. Gornitzka, *Eur. J. Med. Chem.* **2018**, *143*, 1635–1643. c) C. Zhang, C. Hemmert, H. Gornitzka, O. Cuvillier, M. Zhang, R. Wai-Yin Sun, *ChemMedChem* **2018**, *13*, 1218 – 1229.
- [22] L. Ronconi, C. Marzano, P. Zanello, M. Corsini, G. Miolo, C. Maccà, A. Trevisan, D. Fregona, *J. Med. Chem.* **2006**, *49*, 1648–1657.
- [23] M. Sooriyaarachchi, G. N. George, I. J. Pickering, A. Narendran, J. Gailer, *Metallomics* **2016**, *8*, 1170–1176.
- [24] W. Chen, J. Egly, A. I. Poblador-Bahamonde, A. Maise-Francois, S. Bellemin-Lapponnaz, T. Achard, *Dalton Trans.* **2020**, *49*, 3243–3252.
- [25] J. Egly, M. Bouché, W. Chen, A. Maise-François, T. Achard, S. Bellemin-Lapponnaz, *Eur. J. Inorg. Chem.* **2018**, *2018*, 159–166.
- [26] H. M. J. Wang, I. J. B. Lin, *Organometallics* **1998**, *17*, 972–975.
- [27] T. Scattolin, S. P. Nolan, *Trends Chem.* **2020**, *2*, 721–736.
- [28] S. J. Roseblade, A. Ros, D. Monge, M. Alcarazo, E. Álvarez, J. M. Lassaletta, R. Fernández, *Organometallics* **2007**, *26*, 2570–2578.
- [29] M. Iglesias, D. J. Beetsra, J. C. Knight, L.-L. Ooi, A. Stasch, S. Coles, L. Male, M. B. Hursthouse, K. J. Cavell, A. Dervisi, I. A. Fallis, *Organometallics* **2008**, *27*, 3279–3289.
- [30] M. Monticelli, S. Bellemin-Lapponnaz, C. Tubaro, M. Rancan, *Eur. J. Inorg. Chem.* **2017**, *2017*, 2488–2495.
- [31] A. Collado, J. Bohnenberger, M.-J. Oliva-Madrid, P. Nun, D. B. Cordes, A. M. Z. Slawin, S. P. Nolan, *Eur. J. Inorg. Chem.* **2016**, *2016*, 4111–4122.
- [32] N. V. Tzouras, F. Nahra, L. Falivene, L. Cavallo, M. Saab, K. V. Hecke, A. Collado, C. J. Collett, A. D. Smith, C. S. J. Cazin, S. P. Nolan, *Chem. – Eur. J.* **2020**, *26*, 4515–4519.
- [33] P. de Frémont, R. Singh, E. D. Stevens, J. L. Petersen, S. P. Nolan, *Organometallics* **2007**, *26*, 1376–1385.
- [34] A. Collado, A. Gómez-Suárez, A. R. Martin, A. M. Z. Slawin, S. P. Nolan, *Chem. Commun.* **2013**, *49*, 5541.
- [35] M. Baron, C. Tubaro, M. Basato, A. A. Isse, A. Gennaro, L. Cavallo, C. Graiff, A. Dolmella, L. Falivene, L. Caporaso, *Chem. – Eur. J.* **2016**, *22*, 10211–10224.
- [36] M. Baron, C. Tubaro, M. Basato, M. M. Natile, C. Graiff, *J. Organomet. Chem.* **2013**, *723*, 108–114.
- [37] M. Baron, C. Tubaro, M. Basato, A. Biffis, M. M. Natile, C. Graiff, *Organometallics* **2011**, *30*, 4607–4615.
- [38] J. C. Bernhammer, H. V. Huynh, *Organometallics* **2014**, *33*, 1266–1275.
- [39] C. Hirtenlehner, C. Krims, J. Höbling, M. List, M. Zabel, M. Fleck, R. J. F. Berger, W. Schoefberger, U. Monkowius, *Dalton Trans.* **2011**, *40*, 9899–9910.
- [40] This process was investigated on the potential energy surface for a simplified model complex having a hydrogen as nitrogen-imidazole substituent and a methyl group as sulphur substituent. Starting from the chelated complex (with the methyl pointing upward), we have identified several minima on the PES lying at +31.44 kcal mol⁻¹ (a structure in which the Au-S bond is broken), at +34.88 kcal mol⁻¹ (a structure in which the methyl substituent of sulphur as well as the bromine nuclei have rotated by approximately 90 degrees) and at +33.92 kcal mol⁻¹ (a structure in which the methyl has rotated by approximately 90 degrees and is pointing downward).
- [41] The same pathway was investigated also for the simplified model complex. Also in this case, the slightly stabilised reactant complex forms and is converted into the neutral tribromo complex through a low energy barrier (less than 1 kcal mol⁻¹) (Figure S31).
- [42] M. Kriechbaum, J. Höbling, H.-G. Stammer, M. List, R. J. F. Berger, U. Monkowius, *Organometallics* **2013**, *32*, 2876–2884.
- [43] C. Topf, C. Hirtenlehner, M. Zabel, M. List, M. Fleck, U. Monkowius, *Organometallics* **2011**, *30*, 2755–2764.
- [44] F. Schmitt, K. Donnelly, J. K. Muenzner, T. Rehm, V. Novohradsky, V. Brabec, J. Kasparkova, M. Albrecht, R. Schobert, T. Mueller, *J. Inorg. Biochem.* **2016**, *163*, 221–228.
- [45] a) C. Schmidt, B. Karge, R. Misgeld, A. Prokop, R. Franke, M. Brönstrup, I. Ott, *Chem. – Eur. J.* **2017**, *23*, 1869–1880. b) F. Hackenberg, H. Müller-Bunz, R. Smith, W. Streciwilk, X. Zhu, M. Tacke, *Organometallics* **2013**, *32*, 5551–5560. c) F. Hackenberg, M. Tacke, *Dalton Trans.* **2014**, *43*, 8144–8153.
- [46] M. Baron, S. Bellemin-Lapponnaz, C. Tubaro, M. Basato, S. Bogialli, A. Dolmella, *J. Inorg. Biochem.* **2014**, *141*, 94–102.
- [47] G. Boscutti, L. Marchiò, L. Ronconi, D. Fregona, *Chem. – Eur. J.* **2013**, *19*, 13428–13436.
- [48] A. Nandy, T. Samanta, S. Mallick, P. Mitra, S. K. Seth, K. D. Saha, S. S. Al-Deyab, J. Dinda, *New J. Chem.* **2016**, *40*, 6289–6298.
- [49] E. J. Baerends, D. E. Ellis, P. Ros, *Chem. Phys.* **1973**, *2*, 41–51.
- [50] G. te Velde, F. M. Bickelhaupt, E. J. Baerends, C. Fonseca Guerra, S. J. A. van Gisbergen, J. G. Snijders, T. Ziegler, *J. Comput. Chem.* **2001**, *22*, 931–967.
- [51] E. J. Baerends, et al., Computer code ADF2018, SCM, Theoretical Chemistry, Vrije Universiteit, Amsterdam, The Netherlands, **2018**.
- [52] A. D. Becke, *Phys. Rev. A* **1988**, *38*, 3098–3100.
- [53] C. Lee, W. Yang, R. G. Parr, *Phys. Rev. B* **1988**, *37*, 785–789.

-
- [54] S. Grimme, S. Ehrlich, L. Goerigk, *J. Comput. Chem.* **2011**, 32, 1456–1465.
- [55] E. van Lenthe, E. J. Baerends, J. G. Snijders, *J. Chem. Phys.* **1994**, 101, 9783–9792.
- [56] a) F. Zaccaria, L. P. Wolters, C. Fonseca Guerra, L. Orian, *J. Comput. Chem.* **2016**, 37, 1672–1680. b) M. Dalla Tiezza, F. M. Bickelhaupt, L. Orian, *ChemistryOpen* **2019**, 8, 143–154. c) M. Dalla Tiezza, F. M. Bickelhaupt, L. Orian, *ChemPhysChem* **2018**, 19, 1766–1773. d) S. Masood Ahmad, M. Dalla Tiezza, L. Orian, *Catalysts* **2019**, 9, 679. e) L. Orian, F. M. Bickelhaupt, *Synlett* **2021**, 32, 561 – 572. f) A. Madabeni, P. A. Nogara, M. Bortoli, J. B. T. Rocha, L. Orian, *Inorg. Chem.* **2021**, 60, 4646–4656. g) L. Orian, W.-J. van Zeist, F. M. Bickelhaupt, *Organometallics* **2008**, 27, 4028–4030.
- [57] A. D. Becke, *J. Chem. Phys.* **1988**, 88, 2547–2553.
- [58] M. Franchini, P. H. T. Philipsen, L. Visscher, *J. Comput. Chem.* **2013**, 34, 1819–1827.
- [59] a) M. Baron, A. Dall'Anese, C. Tubaro, L. Orian, V. Di Marco, S. Bogialli, C. Graiff, M. Basato, *Dalton Trans.* **2018**, 47, 935–945. b) M. Baron, C. Tubaro, M. L. C. Cairoli, L. Orian, S. Bogialli, M. Basato, M. M. Natile, C. Graiff, *Organometallics* **2017**, 36, 2285–2292. c) V. Stoppa, T. Scattolin, M. Bevilacqua, M. Baron, C. Graiff, L. Orian, A. Biffis, I. Menegazzo, M. Roverso, S. Bogialli, F. Visentin, C. Tubaro, *New J. Chem.* **2021**, 45, 961–971.
- [60] A. Klamt, G. Schüürmann, *J. Chem. Soc. Perkin Trans. 2* **1993**, 799–805.
- [61] A. Klamt, *J. Phys. Chem.* **1995**, 99, 2224–2235.
- [62] C. C. Pye, T. Ziegler, *Theor. Chem. Acc.* **1999**, 101, 396–408.
- [63] N. L. Allinger, X. Zhou, J. Bergsma, *J. Mol. Struct. THEOCHEM* **1994**, 312, 69–83.

Entry for the Table of Contents

Gold(I,III) complexes with N-heterocyclic carbene ligands having a thioether side-arm have been synthesised and fully characterised; their antiproliferative properties have been also evaluated.